(Q41247488)

28 September 2017

1 reference

title

Clozapine for the treatment of psychosis in Parkinson's disease: a review (English)

1 reference

28 September 2017

1 reference

1 reference

Auzou P

1

1 reference

28 September 2017

Ozsancak C

2

1 reference

28 September 2017

Hannequin D

3

1 reference

28 September 2017

Moore N

4

1 reference

28 September 2017

Augustin P

5

1 reference

28 September 2017

language of work or name

English

0 references

publication date

1 November 1996

1 reference

Acta Neurologica Scandinavica

28 September 2017

published in

1 reference

28 September 2017

volume

94

1 reference

28 September 2017

issue

5

1 reference

28 September 2017

page(s)

329-336

1 reference

Effects of levodopa in Parkinsonian patients with dementia.

28 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Behavioral complications of drug treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Antecedent clinical features associated with dementia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

L-dopa long-term treatment in Parkinson's disease: age-related side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Clozapine treatment of parkinsonism with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Clozapine plasma levels and convulsions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Clozapine-related seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

Clozapine treatment of psychosis in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.1996.TB07075.X

10.1111/J.1600-0404.1996.TB07075.X

21 January 2018

Identifiers

DOI

1 reference

28 September 2017

1 reference